| NOVO-NORDISK AS B DK 0,1 |
| Dänemark |
| Gesundheit |
| DK0062498333 / A3EU6F |
| NOV (Frankfurt) |
| FRA:NOV, ETR:NOV, NOV:GR |
| - |
| https://www.novonordisk.c.. |
|
Novo Nordisk A/S is a global pharmaceutical company specializing in research, development, and manufacturing of treatments for serious chronic diseases. Founded through the 1989 merger of Danish insulin pioneers Nordisk Insulaboratorium and Novo Tera..
>Volltext.. |
| 157694.69 Mio. EUR |
| 170409 Mio. EUR |
| 44985.2 Mio. EUR |
| 23198.79 Mio. EUR |
| 15900.79 Mio. EUR |
| 3.58 EUR |
| 19134.94 Mio. EUR |
| 6074.21 Mio. EUR |
| 17832.89 Mio. EUR |
| 0.19 |
| 5.38% |
| 4.61% |
| 1.57 EUR |
| 4.4% |
| 4.38% |
| 14.08.26 - 0.5011875€ 27.03.26 - 1.064076€ >weitere anzeigen... |
| - |
| NOVO NORDISK, NOVONORDISK |
| 01.11.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|